Search

Search Constraints

You searched for: Author/Creator Method, Michael

Search Results

1. A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study. Issue 3 (March 2017)

2. 2022-RA-835-ESGO AGO-OVAR 2.34/MIROVA: A randomized phase II trial of Mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα) high recurrent ovarian cancer eligible for platinum-based chemotherapy. (20th October 2022)

3. 2022-RA-660-ESGO Characterization of extended treatment benefit from three phase 1 and 3 clinical trials examining patients with folate receptor alpha-positive recurrent ovarian cancer treated with single-agent mirvetuximab soravtansine. (20th October 2022)

5. O011/#496 Mirvetuximab soravtansine and bevacizumab in folate receptor αlpha-positive ovarian cancer: efficacy in patients with and without prior bevacizumab. (4th December 2022)

6. O028/#376 Clinical benefit of mirvetuximab soravtansine in ovarian cancer patients with high folate receptor alpha expression: results from the soraya study. (4th December 2022)

7. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology–Gynecologic Oncology Group protocol 240). Issue 3 (March 2015)

8. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology–Gynecologic Oncology Group protocol 240). Issue 3 (March 2015)

9. A Standardized Investigational Ki-67 Immunohistochemistry Assay Used to Assess High-Risk Early Breast Cancer Patients in the monarchE Phase 3 Clinical Study Identifies a Population With Greater Risk of Disease Recurrence When Treated With Endocrine Therapy Alone. Issue 4 (25th April 2022)

10. A Comparison of Sentinel Lymph Node Biopsy to Lymphadenectomy for Endometrial Cancer Staging (FIRES Trial): A Multicentre, Prospective, Cohort Study. Issue 8 (August 2017)